Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-in-Class Ketohexokinase Inhibitor for Metabolic Disorders and Non-Alcoholic Fatty Liver Disease

Scientists characterized the transport/metabolic pathways in the hepatic disposition of PF-06835919, a first-in-class ketohexokinase inhibitor for the treatment of metabolic disorders and non-alcoholic steatohepatitis.